A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects
A Phase I, Single-center, Randomized, Double-blind, Placebo- and Positive-controlled, Four-period, Crossover Clinical Study to Evaluate the Effect of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
72 participants
Mar 7, 2026
INTERVENTIONAL
Conditions
Summary
The aim of this trial is to evaluate the effect of a single oral dose of HDM1002 tablets on the QT/QTc interval in healthy subjects.
Eligibility
Inclusion Criteria5
- The subject has voluntarily signed a written informed consent form.
- Male or female; age between 18 and 45 years (inclusive).
- Subject's weight ≥50 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m2, inclusive. BMI = weight (kg) / height2 (m2).
- Medical history inquiry, physical examination, laboratory test items, and other trial-related tests at screening are all normal or show mild abnormalities with no clinical significance, and the subject is judged to be eligible by the clinical research physician.
- The subject is able to communicate well with the investigator and comply with the protocol requirements to complete the study.
Exclusion Criteria10
- History of or current neurological/psychiatric, respiratory, cardiovascular, gastrointestinal, hematological and lymphatic, endocrine, or musculoskeletal system diseases, hepatic or renal insufficiency, or any other disease or physiological condition that may affect the study results;
- Subjects with a personal or family history of medullary thyroid cancer (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2);
- History of chronic pancreatitis or an episode of acute pancreatitis within 3 months prior to screening;
- History of a cholecystitis episode within 3 months prior to screening;
- History of allergy to HDM1002, moxifloxacin hydrochloride tablets, other fluoroquinolones or quinolones, or any of the excipients; or history of food allergy, or a specific allergy history (asthma, urticaria, eczema, etc.);
- Clinically significant major illness or undergone major surgery within 3 months prior to the trial;
- Blood donation within 3 months, or plans to donate blood during this study, or transfusion or blood loss ≥200 mL within 4 weeks prior to the trial;
- Has consumed a special diet, engaged in strenuous exercise, or had other factors that affect drug absorption, distribution, metabolism, and excretion within 48 hours prior to dosing;
- Pregnant or lactating, or has a positive blood pregnancy test result;
- The investigator believes that the subject has any other condition that makes them unsuitable for participation in this clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
HDM1002 tablet, oral, 200 mg single dose
HDM1002 tablet, oral, 400 mg single dose
Placebo tablet, oral, single dose
Moxifloxacin tablet, oral, 400 mg single dose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07594847